Literature DB >> 9205014

Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial.

C M Gibson1, C P Cannon, R M Greene, R F Sequeira, R D Margorien, F Leya, D J Diver, D S Baim, E Braunwald.   

Abstract

Rescue percutaneous transluminal coronary angioplasty (PTCA) has been used to establish reperfusion after failed thrombolysis, and the goal of this study was to examine the angiographic and clinical outcomes after rescue PTCA performed for an occluded artery 90 minutes after thrombolysis. Four hundred two patients with acute myocardial infarction were randomized to receive either anistreplase (APSAC), recombinant tissue plasminogen activator, or their combination in the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. The angiographic and clinical outcomes of patients with a patent artery 90 minutes after thrombolysis were compared with those of patients with an occluded artery treated in a nonrandomized fashion with either rescue or no rescue PTCA. At 90 minutes, the number of frames required to opacify standard landmarks (corrected TIMI frame count) was significantly lower (i.e., flow was faster) after successful rescue PTCA (27 +/- 11) than that in patent arteries after successful thrombolysis (39 +/- 20, p < 0.001), and the incidence of TIMI grade 3 flow was correspondingly higher after successful rescue PTCA (87% vs 65%, p = 0.002). In-hospital adverse outcomes (death, recurrent acute myocardial infarction, severe congestive heart failure, cardiogenic shock or an ejection fraction <40%) occurred in 29% of successful rescue PTCAs and in 83% of failed rescue PTCAs (p = 0.01). Among all patients in whom rescue PTCA was performed (successes and failures combined), 35% of patients experienced an adverse outcome, which was the same as the 35% incidence observed in patients not undergoing rescue PTCA (p = NS) and tended to be higher than the 23% incidence observed in patients with patent arteries (p = 0.07). Although successful rescue PTCA for an occluded artery at 90 minutes results in restoration of flow that is superior to that of successful thrombolysis, the incidence of adverse events for the strategy of rescue PTCA as a whole was the same as that of undertaking no PTCA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205014     DOI: 10.1016/s0002-9149(97)00277-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  The role of coronary angioplasty and stenting in acute myocardial infarction.

Authors:  A Brodison; R S More; A Chauhan
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

Review 2.  [Interventional therapy of acute myocardial infarction].

Authors:  R Zahn; U Zeymer
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

3.  Restoration of microcirculatory patency after myocardial infarction: results of current coronary interventional strategies and techniques.

Authors:  Marlos R Fernandes; R David Fish; John Canales; Jonathan Aliota; Guilherme V Silva; Emerson C Perin; Macarthur A Elayda; James M Wilson
Journal:  Tex Heart Inst J       Date:  2012

4.  One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial.

Authors:  A G C Sutton; P G Campbell; R Graham; D J A Price; J C Gray; E D Grech; J A Hall; A A Harcombe; R A Wright; R H Smith; J J Murphy; A Shyam-Sundar; M J Stewart; A Davies; N J Linker; M A de Belder
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

5.  Rescue percutaneous coronary intervention for failed thrombolysis: results from a district general hospital.

Authors:  K P Balachandran; J Miller; A C H Pell; B D Vallance; K G Oldroyd
Journal:  Postgrad Med J       Date:  2002-06       Impact factor: 2.401

6.  Tumor necrosis factor-alpha G-238A polymorphism and coronary artery disease risk: a meta-analysis of 4,222 patients and 4,832 controls.

Authors:  Xian-Ping Hua; Xiao-Dong Zhang; Joey Sw Kwong; Xian-Tao Zeng; Zhen-Jian Zhang; Wan-Lin Wei
Journal:  Ther Clin Risk Manag       Date:  2015-09-23       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.